Latest Research
All publications from the Cancer3.AI database, newest first.
Improved progression-free survival following dose-escalated vs. standard dose post-operative radiation therapy for high-risk meningiomas: An International Multicenter Individual Patient Level Meta-Analysis (FIRESTORM).
Singh R, et al
A new international multicenter study called FIRESTORM investigated whether using higher doses of radiation therapy after surgery improves outcomes for patients with high-risk meningiomas, a type of brain tumor. Researchers pooled individual patient data from seven institutions, comparing dose-escalated radiation therapy (DE-RT, defined as a biological effective dose of at least 79.2 Gy) against standard-dose radiation therapy (SD-RT) in 248 patients. The results showed that patients receiving DE-RT had significantly better progression-free survival, with 5-year rates of 65.8% compared to 38.8% for SD-RT, and the benefit held up across multiple statistical analyses including propensity score weighting. While DE-RT was associated with a higher rate of any-grade brain tissue injury called radionecrosis (33.9% vs. 13.2%), the rates of severe radionecrosis (Grade 3 or higher) were similarly low in both groups (5.1% vs. 3.2%), indicating that the dose escalation did not meaningfully increase serious side effects. These findings suggest that dose-escalated post-operative radiation therapy should be considered a preferred treatment strategy for patients with high-risk meningiomas, offering substantially improved tumor control without a significant increase in dangerous toxicity.
International journal of radiation oncology, biology, physics
Source →PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatment.
Chen H, et al
Researchers investigated the role of PIAS4, a SUMO E3 ligase enzyme, in breast cancer progression and its potential as a therapeutic target. The study found that PIAS4 is highly expressed in breast cancer tissue and that elevated levels are associated with poor patient prognosis. Mechanistically, PIAS4 was shown to chemically modify the cell cycle protein CDK6 through a process called SUMOylation, which boosts CDK6 activity, promotes phosphorylation of the tumor suppressor protein RB1, and drives cancer cells through the G1 phase of the cell cycle, enabling uncontrolled proliferation. When PIAS4 was blocked, CDK6 activity dropped, cell cycle progression stalled, and breast cancer cell growth was significantly curtailed both in laboratory models and in mouse tumor experiments. Crucially, combining PIAS4 inhibition with an existing class of cancer drugs called CDK4/6 inhibitors produced a synergistic effect, achieving greater tumor suppression than either treatment alone. These findings suggest that targeting PIAS4 represents a promising new strategy to enhance the effectiveness of current breast cancer therapies.
Oncogene
Source →Dermoscopic features of amelanotic cutaneous melanoma metastases: evidence from four cases.
Campoli M, et al
Researchers from a dermatology team investigated the dermoscopic (skin surface microscopy) characteristics of amelanotic cutaneous melanoma metastases (ACMMs) — a rare form of skin metastasis from malignant melanoma that lacks the typical dark pigmentation. In a case series of four patients, all lesions displayed vascular patterns visible under dermoscopy, with polymorphic vessels and linear irregular or serpentine vessels identified as the most prominent features. Combining these findings with previously published literature reinforces the emerging consensus that vascular patterns are the defining dermoscopic hallmark of ACMMs. Particularly noteworthy was one case in which the primary melanoma was not initially detected, and the metastatic skin lesions were the first sign of disease, highlighting the diagnostic danger these lesions pose. Because ACMMs can mimic benign skin conditions, establishing clear dermoscopic criteria is essential to help clinicians recognize these potentially life-threatening lesions earlier. This study adds important evidence toward defining those criteria and underscores the need for larger, systematic investigations.
Dermatology reports
Source →Comprehensive Immunohistochemical Analysis of Atypical Fibroxanthoma: Focus on PRAME in Differential Diagnosis.
Gungor Sahin G, et al
Researchers conducted a retrospective study of 15 cases of atypical fibroxanthoma (AFX), a rare skin tumor that primarily affects elderly patients in sun-exposed areas, to better understand how to distinguish it from more dangerous cancers like malignant melanoma. The team performed extensive immunohistochemical testing — a laboratory technique that uses antibodies to identify specific proteins in tissue — with a particular focus on a newly applied marker called PRAME. The key findings revealed that all AFX cases showed strong, uniform positivity for the protein CD10, while every case tested completely negative for PRAME, a marker commonly expressed in malignant melanoma. After a mean follow-up period of seven years, all patients remained alive, confirming the generally favorable prognosis of AFX. These results suggest that combining the absence of PRAME expression with the presence of block-type CD10 staining can serve as a reliable diagnostic tool to separate AFX from melanoma and other aggressive look-alike tumors, helping clinicians avoid unnecessary overtreatment.
The American Journal of dermatopathology
Source →A novel hairless highly immunodeficient mice model optimized for in vivo imaging.
Matsuda K, et al
Researchers developed a novel mouse model called Hairless Rag2/Jak3 knockout (Hairless R/J) mice, designed to improve the quality of live imaging in cancer research. These mice are both hairless and severely immunodeficient, lacking functional T, B, and NK immune cells, which allows human cancer cells to be transplanted without rejection. Compared to previously used Nude R/J mice, the new model has thinner skin and superior optical transparency, enabling clearer detection of fluorescent signals from implanted tumor cells. In laboratory tests, human cholangiocarcinoma and malignant melanoma cell lines were successfully transplanted and monitored in real time using fluorescence imaging. This improved model will allow scientists to observe tumor growth and evaluate new anticancer treatments more precisely and non-invasively, potentially accelerating the development of effective cancer therapies.
Laboratory animal research
Source →